New treatment option for active lupus nephritis!
Clinical trials show that using voclosporin with mycophenolate mofetil is more effective at stopping lupus nephritis from getting worse than mycophenolate mofetil alone. This option is recommended for treating active class 3 to 5 lupus nephritis in adults. The cost-effectiveness estimates are within what NICE considers acceptable for NHS resources.
Recent Posts
Catalyzing Cardiovascular Health Innovation through Urban Interventions and Collaborative Research
Cardiovascular health innovation is at the forefront of the Innovative Health Initiative (IHI), the world's largest public-private partnership in life sciences, which succeeds the Innovative Medicines Initiative (IMI). Key projects from IHI Call 8, such as Cities@Heart, target cardiovascular dise...
EMA Approval Submission for Teclistamab Multiple Myeloma Monotherapy
Johnson & Johnson has submitted a Type II variation application to the European Medicines Agenc...
European Cancer Care: Balancing Economic Stability with Improved Survival Rates
European Cancer Care has achieved substantial improvements in survival rates without a disproportionate escalation in health budgets, as evidenced by the